Minireview: Toward the establishment of a link between melatonin and glucose homeostasis: Association of melatonin mt2 receptor variants with type 2 diabetes

Molecular Endocrinology

Volumn 27, Issue 8, 2013, Pages 1217-1233

  Karamitri, Angeliki ^a,b,c   Renault, Nicolas ^d   Clement, Nathalie ^a,b,c   Guillaume, Jean Luc ^a,b,c   Jockers, Ralf ^a,b  

^a INSERM   (France)

^b Centre Natinal de la Recherche Scientifique UnitéMixte de Recherche 8104   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Cité scientifique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CRYPTOCHROME 1; CRYPTOCHROME 2; CYCLIC GMP DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; LEPTIN; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PER1 PROTEIN; PER2 PROTEIN; PER3 PROTEIN; PROTEIN; PROTEIN BCL XL; PROTEIN BMAL1; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG;

AGING; AMINO ACID SUBSTITUTION; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; DRUG POTENTIATION; EXON; EXPERIMENTAL MODEL; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HETEROZYGOTE; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KNOCKOUT MOUSE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MOLECULAR MODEL; MTNR1B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS FUNCTION; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PERSONALIZED MEDICINE; PINEALECTOMY; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOZOCIN DIABETES; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; SUPRACHIASMATIC NUCLEUS;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; MELATONIN; MICE; MOLECULAR SEQUENCE DATA; OBESITY; PINEAL GLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880774466     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1101     Document Type: Review

References (123)

1. Vassilatis DK, Hohmann JG, Zeng H, et al. TheGprotein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA. 2003;100:4903-4908.
2. Fredriksson R, Schiöth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol. 2005;67: 1414-1425.
3. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature. 2013;494:185-194.
4. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356-363.
5. Vassart G, Costagliola S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol. 2011;7:362-372.
6. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 2003;43:381-411.
7. Small KM, Tanguay DA, Nandabalan K, Zhan P, Stephens JC, Liggett SB. Gene and protein domain-specific patterns of genetic variability within the G-protein coupled receptor superfamily. Am J Pharmacogenomics. 2003;3:65-71.
8. Lee A, Rana BK, Schiffer HH, et al. Distribution analysis of nonsynonymous polymorphisms within the G-protein-coupled receptor gene family. Genomics. 2003;81:245-248.
9. Spanakis E, Milord E, Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. J Cell Physiol. 2008;217:605-617.
10. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348:1085-1095.
11. Xiang Z, Litherland SA, Sorensen NB, et al. Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist. Biochemistry. 2006;45:7277-7288.
12. Thompson MD, Burnham WM, Cole DE. The G protein-coupled receptors: pharmacogenetics and disease. Crit Rev Clin Lab Sci. 2005;42:311-392.
13. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther. 2011;89:366-378.
14. Kazius J, Wurdinger K, van Iterson M, Kok J, Bäck T, Ijzerman AP. GPCR NaVa database: natural variants in human G proteincoupled receptors. Hum Mutat. 2008;29:39-44.
15. Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41: 77-81.
16. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009; 41:89-94.
17. Xia Q, Chen ZX, Wang YC, et al. Association between the melatonin receptor 1B gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis. PLoS One. 2012;7:e50107.
18. Kelliny C, Ekelund U, Andersen LB, et al. Common genetic determinants of glucose homeostasis in healthy children: the European Youth Heart Study. Diabetes. 2009;58:2939-2945.
19. Barker A, Sharp SJ, Timpson NJ, et al. Association of genetic Loci with glucose levels in childhood and adolescence: a meta-analysis of over 6,000 children. Diabetes. 2011;60:1805-1812.
20. Walford GA, Green T, Neale B, et al. Common genetic variants differentially influence the transition from clinically defined states of fasting glucose metabolism. Diabetologia. 2012;55:331-339.
21. Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41:82-88.
22. Langenberg C, Pascoe L, Mari A, et al. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. Diabetologia. 2009;52: 1537-1542.
23. Liao S, Liu Y, Tan Y, et al. Association of genetic variants of melatonin receptor 1B with gestational plasma glucose level and risk of glucose intolerance in pregnant Chinese women. PLoS One. 2012;7:e40113.
24. Mao H, Li Q, Gao S. Meta-analysis of the relationship between common type 2 diabetes risk gene variants with gestational diabetes mellitus. PLoS One. 2012;7:e45882.
25. Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol. 2008;154:1182-1195.
26. Li C, Shi Y, You L, Wang L, Chen ZJ. Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome. Gynecol Obstet Invest. 2011;72:130-134.
27. Bonnefond A, Clément N, Fawcett K, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet. 2012;44:297-301.
28. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010; 62:343-380.
29. Chakrabarti P, Chakrabarti S. C-H. O hydrogen bond involving proline residues in α-helices. J Mol Biol. 1998;284:867-873.
30. Huang YH, Chen CM. Statistical analyses and computational prediction of helical kinks in membrane proteins. J Comput Aided Mol Des. 2012;26:1171-1185.
31. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. β2 Adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem. 2002;277:40989-40996.
32. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289: 739-745.
33. Pardo L, Deupi X, Dölker N, López-Rodríguez ML, Campillo M. The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. Chembiochem. 2007;8:19-24.
34. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature. 2008;454:183-187.
35. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
36. Boden G, Ruiz J, Urbain JL, Chen X. Evidence for a circadian rhythm of insulin secretion. Am J Physiol Endocrinol Metab. 1996;271:E246-E252.
37. Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod. 1998; 3:13-22.
38. Kennaway DJ, Voultsios A, Varcoe TJ, Moyer RW. Melatonin in mice: rhythms, response to light, adrenergic stimulation, and metabolism. Am J Physiol Regul Integr Comp Physiol. 2002;282: R358-R365.
39. Ebihara S, Marks T, Hudson DJ, Menaker M. Genetic control of melatonin synthesis in the pineal gland of the mouse. Science. 1986;231:491-493.
40. Hardeland R. Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3:194-225.
41. Watson RR. Melatonin in the Promotion of Health. 2nd ed: CRC Press; 2012
42. Diaz B, Blázquez E. Effect of pinealectomy on plasma glucose, insulin and glucagon levels in the rat. Horm Metab Res. 1986;18: 225-229.
43. Rodríguez V, Mellado C, Alvarez E, De Diego JG, Blázquez E. Effect of pinealectomy on liver insulin and glucagon receptor concentrations in the rat. J Pineal Res. 1989;6:77-88.
44. Lima FB, Machado UF, Bartol I, et al. Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Physiol. 1998;275:E934-E941.
45. Lima FB, Matsushita DH, Hell NS, Dolnikoff MS, Okamoto MM, Cipolla Neto J. The regulation of insulin action in isolated adipocytes. Role of the periodicity of food intake, time of day and melatonin. Braz J Med Biol Res. 1994;27:995-1000.
46. Zanquetta MM, Seraphim PM, Sumida DH, Cipolla-Neto J, Machado UF. Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. J Pineal Res. 2003;35: 141-148.
47. Zalatan F, Krause JA, Blask DE. Inhibition of isoproterenol-induced lipolysis in rat inguinal adipocytes in vitro by physiological melatonin via a receptor-mediated mechanism. Endocrinology. 2001;142:3783-3790.
48. Brydon L, Petit L, Delagrange P, Strosberg AD, Jockers R. Functional expression of mt2 (mel1b) melatonin receptors in human paz6 adipocytes. Endocrinology. 2001;142:4264-4271.
49. BizotEspiard JG, Double A, Cousin B, et al. Lack of melatonin effects on insulin action in normal rats. Hormone Metab Res. 1998;30:711-716.
50. Kosa E, Maurel D, Siaud P. Effects of pinealectomy on glucagon responsiveness to hypoglycaemia induced by insulin injections in fed rats. Exp Physiol. 2001;86:617-620.
51. Nogueira TC, Lellis-Santos C, Jesus DS, et al. Absence of melatonin induces night-time hepatic insulin resistance and increased gluconeogenesis due to stimulation of nocturnal unfolded protein response. Endocrinology. 2011;152:1253-1263.
52. Radziuk J, Pye S. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia. 2006;49:1619-1628.
53. Venegas C, García JA, Doerrier C, et al. Analysis of the daily changes of melatonin receptors in the rat liver. J Pineal Res. 2013; 54:313-321.
54. Picinato MC, Haber EP, Carpinelli AR, Cipolla NJ. Daily rhythm of glucose-induced insulin secretion by isolated islets from intact and pinealectomized rat. J Pineal Res. 2002;33:172-177.
55. Kocher L, Brun J, Borson-Chazot F, Gonnaud PM, Claustrat B. Increased REM sleep associated with melatonin deficiency after pinealectomy: a case study. Chronobiol Int. 2006;23:889-901.
56. Etain B, Dumaine A, Bellivier F, et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Genet. 2012;21:4030-4037.
57. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17:83-93.
58. Chien IC, Chang KC, Lin CH, Chou YJ, Chou P. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a populationbased national health insurance study. Gen Hosp Psychiatry. 2010;32:577-582.
59. Salvi V, D'Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65:47-54.
60. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010;126:366-387.
61. Champney TH, Brainard GC, Richardson BA, Reiter RJ. Experimentally-induced diabetes reduces nocturnal pineal melatonin content in the Syrian hamster. Comp Biochem Physiol A Comp Physiol. 1983;76:199-201.
62. Peschke E, Frese T, Chankiewitz E, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40:135-143.
63. Frese T, Bach AG, Mühlbauer E, et al. Pineal melatonin synthesis is decreased in type 2 diabetic Goto-Kakizaki rats. Life Sci. 2009; 85:526-533.
64. Sartori C, Dessen P, Mathieu C, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150:5311-5317.
65. Nishida S, Segawa T, Murai I, Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Δ-5 desaturase activity. J Pineal Res. 2002;32:26-33.
66. Peschke E, Schucht H, Mühlbauer E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. J Pineal Res. 2010;49:373-381.
67. Wei M, Ong L, Smith MT, et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2003;12:44-50.
68. Paskaloglu K, Sener G, Ayanǧolu-Dülger G. Melatonin treatment protects against diabetes-induced functional and biochemical changes in rat aorta and corpus cavernosum. Eur J Pharmacol. 2004;499:345-354.
69. Kanter M, Uysal H, Karaca T, Sagmanligil HO. Depression of glucose levels and partial restoration of pancreatic _-cell damage by melatonin in streptozotocin-induced diabetic rats. Arch Toxicol. 2006;80:362-369.
70. Simsek N, Kaya M, Kara A, Can I, Karadeniz A, Kalkan Y. Effects of melatonin on islet neogenesis and β cell apoptosis in streptozotocin-induced diabetic rats: an immunohistochemical study. Domest Anim Endocrinol. 2012;43:47-57.
71. Picinato MC, Hirata AE, Cipolla-Neto J, et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res. 2008;44:88-94.
72. de Lima LM, dos Reis LC, de Lima MA. Influence of the pineal gland on the physiology, morphometry and morphology of pancreatic islets in rats. Braz J Biol. 2001;61:333-340.
73. Hikichi T, Tateda N, Miura T. Alteration of melatonin secretion in patients with type 2 diabetes and proliferative diabetic retinopathy. Clin Ophthalmol. 2011;5:655-660.
74. McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. Jama. 2013;309:1388-1396.
75. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology. 1999;140:1009-1012.
76. Wolden-Hanson T, Mitton DR, McCants RL, et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology. 2000;141:487-497.
77. Prunet-Marcassus B, Desbazeille M, Bros A, et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology. 2003;144:5347-5352.
78. She M, Deng X, Guo Z, et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/ high-sucrose-fed rats. Pharmacol Res. 2009;59:248-253.
79. Mühlbauer E, Gross E, Labucay K, Wolgast S, Peschke E. Loss of melatonin signalling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol. 2009; 606:61-71.
80. Bähr I, Mühlbauer E, Schucht H, Peschke E. Melatonin stimulates glucagon secretion in vitro and in vivo. J Pineal Res. 2011;50:336-344.
81. Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring). 2010;18:1861-1863.
82. Pulimeno P, Mannic T, Sage D, et al. Autonomous and self-sustained circadian oscillators displayed in human islet cells. Diabetologia. 2013;56:497-507.
83. Gillette MU, McArthur AJ. Circadian actions of melatonin at the suprachiasmatic nucleus. Behav Brain Res. 1996;73:135-139.
84. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet 15 Spec No. 2006;2:R271-R277.
85. Yoshino J, Imai S. A clock ticks in pancreatic β cells. Cell Metab. 2010;12:107-108.
86. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330:1349-1354.
87. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. 1993;49:654-664.
88. Simonneaux V. Naughty melatonin: how mothers tick off their fetus. Endocrinology. 2011;152:1734-1738.
89. von Gall C, Weaver DR, Moek J, Jilg A, Stehle JH, Korf HW. Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. Ann NY Acad Sci. 2005;1040:508-511.
90. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106:4453-4458.
91. Kroenke CH, Spiegelman D, Manson J, Schernhammer ES, Colditz GA, Kawachi I. Work characteristics and incidence of type 2 diabetes in women. Am J Epidemiol. 2007;165:175-183.
92. Woon PY, Kaisaki PJ, Bragança J, et al. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci U S A. 2007;104:14412-14417.
93. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105-116.
94. Below JE, Gamazon ER, Morrison JV, et al. Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia. 2011;54:2047-2055.
95. Yamamoto H, Nagai K, Nakagawa H. Role of SCN in daily rhythms of plasma glucose, FFA, insulin and glucagon. Chronobiol Int. 1987;4:483-491.
96. Ruiter M, La Fleur SE, van Heijningen C, van der Vliet J, Kalsbeek A, Buijs RM. The daily rhythm in plasma glucagon concentrations in the rat is modulated by the biological clock and by feeding behavior. Diabetes. 2003;52:1709-1715.
97. Sadacca LA, Lamia KA, deLemos AS, Blum B, Weitz CJ. An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice. Diabetologia. 2011; 54:120-124.
98. Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010;466:627-631.
99. Marcheva B, Ramsey KM, Bass J. Circadian genes and insulin exocytosis. Cell Logist. 2011;1:32-36.
100. Dalle S, Ravier MA, Bertrand G. Emerging roles for β-arrestin-1 in the control of the pancreatic _-cell function and mass: new therapeutic strategies and consequences for drug screening. Cell Signal. 2011;23:522-528.
101. Dunning BE, Foley JE, Ahrén B. α Cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005; 48:1700-1713.
102. Habener JF, Stanojevic V. α-Cell role in β-cell generation and regeneration. Islets. 2012;4:188-198.
103. Hope KM, Tran PO, Zhou H, Oseid E, Leroy E, Robertson RP. Regulation of α-cell function by the β-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis. Diabetes. 2004;53:1488-1495.
104. Raju B, Cryer PE. Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon? Am J Physiol Endocrinol Metab. 2005;289:E181-186.
105. Diao J, Asghar Z, Chan CB, Wheeler MB. Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic α-cells. J Biol Chem. 2005;280:33487-33496.
106. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell. 2012;150:1223-1234.
107. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8:369-385.
108. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic β cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol. 2002;191:157-166.
109. Peschke E, Bach AG, Mühlbauer E. Parallel signaling pathways of melatonin in the pancreatic β-cell. J Pineal Res. 2006;40:184-191.
110. Mühlbauer E, Peschke E. Evidence for the expression of both the MT1-and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and β-cell. J Pineal Res. 2007;42:105-106.
111. Peschke E, Stumpf I, Bazwinsky I, Litvak L, Dralle H, Mühlbauer E. Melatonin and type 2 diabetes-a possible link? J Pineal Res. 2007;42:350-358.
112. Ramracheya RD, Muller DS, Squires PE, et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res. 2008;44:273-279.
113. Nagorny CL, Sathanoori R, Voss U, Mulder H, Wierup N. Distribution of melatonin receptors in murine pancreatic islets. J Pineal Res. 2011;50:412-417.
114. O'Brien IA, Lewin IG, O'Hare JP, Arendt J, Corrall RJ. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol (Oxf). 1986;24:359-364.
115. Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell. 2012;148:1160-1171.
116. Peschke E, Mühlbauer E, Musshoff U, Csernus VJ, Chankiewitz E, Peschke D. Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res. 2002;33:63-71.
117. Mühlbauer E, Albrecht E, Bazwinsky-Wutschke I, Peschke E. Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. J Pineal Res. 2012;52:446-459.
118. Antoine MH, Hermann M, Herchuelz A, Lebrun P. Sodium nitroprusside inhibits glucose-induced insulin release by activating ATP-sensitive K+ channels. Biochim Biophys Acta. 1993;1175: 293-301.
119. Stumpf I, Mühlbauer E, Peschke E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic β-cells. J Pineal Res. 2008;45:318-327.
120. Stumpf I, Bazwinsky I, Peschke E. Modulation of the cGMP signaling pathway by melatonin in pancreatic β-cells. J Pineal Res. 2009;46:140-147.
121. Bähr I, Mühlbauer E, Albrecht E, Peschke E. Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Gαq protein-coupled and PI3K signaling pathways. J Pineal Res. 2012;53:390-398.
122. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990; 215:403-410.
123. Suzek BE, Huang H, McGarvey P, Mazumder R, Wu CH. UniRef: comprehensive and non-redundant UniProt reference clusters. Bioinformatics. 2007;23(10):1282-1288.